Loading
A phase 3 trial of Izalontamab brengitecan, Tislelizumab, Carboplatin in small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) is a phase 3 interventional study registered as NCT07502300 by Sichuan Baili Pharmaceutical Co., Ltd., with 562 participants planned, started 2026-06-15 and due to reach its primary completion in 2029-12. Interventions recorded: BL-B01D1, Tislelizumab, Carboplatin, Etoposide. Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares SystImmune / Sichuan Biokin, Extensive-stage small-cell lung cancer, Etoposide, Carboplatin.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares SystImmune / Sichuan Biokin, Extensive-stage small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Tislelizumab, Extensive-stage small-cell lung cancer, Etoposide, Carboplatin.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Tislelizumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.